Skip to main content

Table 1 Demographics and baseline characteristics of patients included in the analysis

From: Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

  Patients, N = 639
Age at onset of symptoms, years (n = 517) 1.5 (0.3, 4.0)
Age at diagnosis, years (n = 582) 3.1 (1.0, 6.7)
Age at first treatment, years 6.2 (2.1, 18.2)
Age at first treatment, n (%)
 0–5 years 310 (48.5)
 6–11 years 189 (29.6)
 12–17 years 75 (11.7)
 18–29 years 45 (7.0)
  > 29 years 20 (3.1)
Time on treatment, months 56.3 (18.2, 97.6)
Time in HOS, months 46.8 (9.6, 93.0)
Treatment started at or after HOS entry, n (%) 233 (36.5)
Deceased, n (%) 97 (15.2)
Age at death, years (n = 97) 15.9 (10.6, 28.0)
Cognitive impairment (at any time), n (%) (n = 626)
 Yes 385 (61.5)
 No 241 (38.5)
Last-reported functional classification, n (%) (n = 467)
 Normal 179 (38.3)
 Borderline 51 (10.9)
 Educable 40 (8.6)
 Trainable 71 (15.2)
 Profoundly impaired 126 (27.0)
  1. Data are presented as median (10th, 90th percentiles) unless stated otherwise. Data were available for all patients included in the analysis (N = 639) unless stated otherwise. HOS, Hunter Outcome Survey